Navigation Links
Synedgen Announces Issuance of Patent to Optimize Animal Health
Date:3/22/2013

Claremont CA (PRWEB) March 22, 2013

Synedgen Inc., a bio-pharmaceutical company developing novel therapies to prevent and treat infection and inflammation, announces that the United States Patent and Trademark Office (USPTO) has issued patent claims for the use of chitosan derivatives to treat or inhibit infections, and optimize animal health and weight gain to allow for the use of lower doses of antibacterial agents in animal feed. This issuance, U.S. Patent No. 8,399,635 Chitosan derivatives to treat animals or optimize animal health, continues the expansion of Synedgen’s patent portfolio.

The full patent covers methods of inhibiting the growth of or killing of bacteria, reducing bacterial load, preventing or delaying the onset of an infection, disease or disorder in an animal subject, and includes preparation, dosage and administration methods.

“The issuance of these claims enhances the strength of our growing IP portfolio,” stated Synedgen President Shenda Baker. “It describes the utility of our chitosan derivatives for infection control in food animals as well as the ability to synergize with traditional antibiotics used in their feed, dramatically reducing the amount of antibiotic used. These claims also complement the launch of Synoplex®, Synedgen’s veterinary wound rinse product designed to treat infected, chronic and non-infected wounds in elephants and rhinoceros.”

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Cla
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
3. Probiotic Action Announces Probiotics Pending Listing on EU Foods
4. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
5. Neogen Corporation Announces 3rd Quarter Results Conference Call
6. Medifirst Solutions, Inc. Announces Further Update To Shareholders
7. Elsevier Announces the Launch of a New Journal: Wound Medicine
8. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
9. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
10. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
11. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 The Conference ... Disruptive Innovations to Advance Clinical Trials conference taking place ... in Boston, MA. , Disruptive thinkers from Novartis, ... more share bold approaches to reduce expensive infrastructure, engage ... innovation needs to be big, or novel, or it ...
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
(Date:5/22/2013)... May 22, 2013 Express Diagnostics ... Pty Ltd are pleased to announce a sponsorship ... Australian and New Zealand distributor of DrugCheck® onsite testing ... Team participated in the Austin 400 May 17-19 in ... an agreement that involves each car of the Erebus ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2
... ball-shaped structure that suggests several interesting possibilities for motion ... of electrons through a bucky ball in a transistor ... its center of mass. Moreover, since bucky balls look ... they may be useful as lubricants for use in ...
... Squibb,Company (NYSE: BMY ) announced today that ... approval of IXEMPRA(TM) (ixabepilone) as,monotherapy for the treatment ... in patients whose tumors are resistant or refractory,to ... granted,approval of IXEMPRA in combination with capecitabine for ...
... 16 MacroChem,(OTC Bulletin Board: MACM) will participate ... the Hilton New York on October 18 and ... outside the Sutton Room, throughout each day of,the ... DeLuccia, will provide a company overview, including discussion ...
Cached Biology Technology:Bouncing bucky balls 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City 2MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City 3
(Date:5/22/2013)... 22, 2013)The omega 3 fatty acids in fish oil ... much so that the American Heart Association currently recommends ... particularly fatty varieties rich in omega 3s. However, the ... In a new study, scientists led by Jason R. ... phenomenon by providing evidence that fish oil might specifically ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
(Date:5/22/2013)... Legionella pneumophila bacteria is responsible for legionellosis, an ... to infect us, this pathogen has developed a complex ... in our cells, thus avoiding these acting against the ... research centre, CIC bioGUNE, in which teams from the ... the National Supercomputation Centre in Barcelona (BSC) have also ...
Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... at Memorial Sloan-Kettering Cancer Center have discovered that a new ... -- work best in patients with mutations in the BRAF ... in the growth and survival of cancer cells and is ... a minority of patients with colon, breast, and lung cancers. ...
... stave off an imminent global extinction crisis, according to ... National Academy of Sciences ( www.pnas.org ). , Conducted ... the Alliance for Zero Extinction (AZE –? www.zeroextinction.org ), ... each of which is in need of urgent conservation ...
... Amazon tropical forests are old. Really old, in fact, which ... Brazilian researchers studying tree growth in the world's largest tropical ... UC Irvine's Susan Trumbore, found that up to half of ... than 300 years old. Some of the trees, Trumbore said, ...
Cached Biology News:Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2Amazon trees much older than assumed, raising questions on global climate impact of region 2
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Biology Products: